trbF Antibody

Introduction to TrkB Antibodies

TrkB antibodies are immunological tools targeting the TrkB receptor, a tyrosine kinase critical for brain-derived neurotrophic factor (BDNF) signaling. These antibodies modulate TrkB activity, enabling research into neurological disorders, cellular survival, and synaptic plasticity .

TrkB Structure and Antibody Binding

The TrkB receptor exists in two isoforms:

• Full-length TrkB (145 kDa): Membrane-bound with tyrosine kinase activity.

• Truncated TrkB-T1 (95 kDa): Lacks the kinase domain, prevalent in non-neuronal tissues .

Antibodies bind distinct epitopes:

Functional Diversity of TrkB Antibodies

• Agonist Antibodies:

  • ZEB85: Fully human scFv-Fc fusion with BDNF-like neuroprotective effects (EC₅₀ = 0.5 nM) .

  • AS86: Rescues Aβ-induced apoptosis in PC12 cells (EC₅₀ = 0.039 nM) .

• Partial Agonists/Antagonists:

  • Antibodies like 29D7 show species-specific activity (100 pM in humans vs. mice) .

Tissue-Specific Challenges

• Platelet vs. Neural TrkB:

  • 7/10 antibodies detected TrkB-T1 in platelets, but only NBP2-52524 identified full-length TrkB .

  • Glycosylation differences cause molecular weight shifts (95 kDa in platelets vs. 90 kDa in cortex) .

Therapeutic Potential

TrkB agonist antibodies offer advantages over BDNF:

• Improved Pharmacokinetics: Longer half-life and blood-brain barrier penetration .

• Reduced Immunogenicity: Fully human formats (e.g., ZEB85) avoid neutralizing antibodies .

• Disease Models:

  • Alzheimer’s Disease: AS86 reverses Aβ toxicity .

  • Obesity/Metabolic Disorders: 38B8 reduces body weight in primates .

Limitations and Controversies

• Antibody Specificity: Only 2/10 commercial antibodies consistently detect full-length TrkB in platelets .

• Glycosylation Sensitivity: PNGase F treatment does not resolve epitope recognition issues, suggesting non-glycan mechanisms .

• p75NTR Cross-Reactivity: None observed in functional assays .